Australian Pharmaceutical Industries Limited announced that Ms. Kylie Elizabeth Barrie has resigned as Deputy General Counsel and Joint Company Secretary of the company effective 29 January 2019 to pursue a new opportunity. The Board of API also advises that it has determined the role of Senior Independent Director is no longer required as the Chair of API, Mr. Mark Smith, is now independent. Mr. Gunderson-Briggs who has occupied this role will continue in his role as an independent Non-executive Director of API, Chairman of the Audit and Risk Committee and a member of the Remuneration Committee.